Dominion Pharmakine scientists have demonstrated in collaboration with Charles A Dinarello (Denver, CO) that hepatic production of interleukin-18 (interferon gamma-inducing factor) regulates melanoma metastasis by increasing tumor cell adhesion to endothelial cells, tumor cell growth at metastatic sites and tumor angiogenesis. Each of these mechanisms are inhibited by exogenous IL-18 binding protein suggesting that IL-18 binding protein may be a potent metastasis preventive biologic for those melanoma patients at high risk of systemic dissemination.